Mylan’s Acquisition of Famy Care Limited Businesses

On February 2, 2015, Mylan Inc. announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain female health care businesses from Famy Care Limited, a specialty women’s health care company with global leadership in generic oral contraceptive products (OCPs) for $750 million in cash plus additional contingent payments of up to $50 million. Cravath represented Mylan in connection with this transaction, which is expected to close in the second half of 2015, subject to regulatory approvals and certain closing conditions.

The Cravath team was led by partners Mark I. Greene and Minh Van Ngo and included associates Kyle C. Harmon and Zara Bari on M&A matters; associate Stephen R. Severo on tax matters; associates Jonathan J. Katz and Matthew J. Bobby on executive compensation and benefits matters; partner Matthew Morreale on environmental matters and partner David J. Kappos on intellectual property matters. Christopher P. Davis also worked on intellectual property matters.